| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | BRD-K19103580 | CTRPv2 | pan-cancer | AAC | -0.0024 | 0.9 |
| mRNA | Vandetanib | CCLE | pan-cancer | AAC | -0.003 | 0.9 |
| mRNA | Doxorubicin | GDSC1000 | pan-cancer | AAC | 0.0021 | 1 |
| mRNA | salermide:PLX-4032 (12:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.0022 | 1 |
| mRNA | B02 | CTRPv2 | pan-cancer | AAC | 0.0021 | 1 |
| mRNA | Talazoparib | GDSC1000 | pan-cancer | AAC | 0.0019 | 1 |
| mRNA | ATRA | GDSC1000 | pan-cancer | AAC | -0.0019 | 1 |
| mRNA | MST-312 | CTRPv2 | pan-cancer | AAC | 0.0019 | 1 |
| mRNA | MPS-1-IN-1 | GDSC1000 | pan-cancer | AAC | -0.0017 | 1 |
| mRNA | temsirolimus | GDSC1000 | pan-cancer | AAC | -0.0017 | 1 |